Literature DB >> 19051325

Promoter methylation blocks FES protein-tyrosine kinase gene expression in colorectal cancer.

Jonathan M Shaffer1, Thomas E Smithgall.   

Abstract

The FES locus encodes a unique nonreceptor protein-tyrosine kinase (FES) traditionally viewed as a proto-oncogene but more recently implicated as a tumor suppressor in colorectal cancer (CRC). Recent studies have demonstrated that while FES is expressed in normal colonic epithelium, expression is lost in tumor tissue and colorectal cancer cell lines, a finding common among tumor suppressors. Here we provide compelling evidence that promoter methylation is an important mechanism responsible for downregulation of FES gene expression in colorectal cancer cells. Treatment with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine resulted in the expression of functional FES transcripts in all CRC cell lines examined, including Caco-2, COLO 320, DLD-1, HCT 116, SNU-1040, SW-480, and HT-29. Bisulfite sequencing of genomic DNA isolated from 5-aza-2'-deoxycytidine-treated HT-29 cells identified methylated CpG dinucleotides immediately upstream from the FES transcription initiation sites. In contrast, this region of the FES promoter was hypomethylated in genomic DNA from normal colonic epithelium. In addition, methylation completely blocked the activity of the FES promoter in reporter gene assays. Promoter methylation is a previously unrecognized mechanism by which FES expression is suppressed in CRC cell lines, and is consistent with a tumor suppressor role for FES in this tumor site despite its tyrosine kinase activity. Copyright 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19051325      PMCID: PMC2648816          DOI: 10.1002/gcc.20638

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  44 in total

1.  A component of the transcriptional repressor MeCP1 shares a motif with DNA methyltransferase and HRX proteins.

Authors:  S H Cross; R R Meehan; X Nan; A Bird
Journal:  Nat Genet       Date:  1997-07       Impact factor: 38.330

Review 2.  Detection and interpretation of altered methylation patterns in cancer cells.

Authors:  Toshikazu Ushijima
Journal:  Nat Rev Cancer       Date:  2005-03       Impact factor: 60.716

Review 3.  The c-Fes family of protein-tyrosine kinases.

Authors:  T E Smithgall; J A Rogers; K L Peters; J Li; S D Briggs; J M Lionberger; H Cheng; A Shibata; B Scholtz; S Schreiner; N Dunham
Journal:  Crit Rev Oncog       Date:  1998

4.  The myeloid-cell-specific c-fes promoter is regulated by Sp1, PU.1, and a novel transcription factor.

Authors:  A Heydemann; G Juang; K Hennessy; M S Parmacek; M C Simon
Journal:  Mol Cell Biol       Date:  1996-04       Impact factor: 4.272

5.  The fps/fes tyrosine kinase is expressed in myeloid, vascular endothelial, epithelial, and neuronal cells and is localized in the trans-golgi network.

Authors:  J Haigh; J McVeigh; P Greer
Journal:  Cell Growth Differ       Date:  1996-07

6.  Expression of two myeloid cell-specific genes requires the novel transcription factor, c-fes expression factor.

Authors:  A Heydemann; J H Boehmler; M C Simon
Journal:  J Biol Chem       Date:  1997-11-21       Impact factor: 5.157

7.  An identity crisis for fps/fes: oncogene or tumor suppressor?

Authors:  Waheed Sangrar; Ralph A Zirgnibl; Yan Gao; William J Muller; Zongchao Jia; Peter A Greer
Journal:  Cancer Res       Date:  2005-05-01       Impact factor: 12.701

8.  A growth-suppressive function for the c-fes protein-tyrosine kinase in colorectal cancer.

Authors:  Frank J Delfino; Heather Stevenson; Thomas E Smithgall
Journal:  J Biol Chem       Date:  2006-02-02       Impact factor: 5.157

9.  The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53.

Authors:  K D Robertson; P A Jones
Journal:  Mol Cell Biol       Date:  1998-11       Impact factor: 4.272

Review 10.  Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?

Authors:  Stephen B Baylin; Joyce E Ohm
Journal:  Nat Rev Cancer       Date:  2006-02       Impact factor: 60.716

View more
  6 in total

1.  Fes tyrosine kinase expression in the tumor niche correlates with enhanced tumor growth, angiogenesis, circulating tumor cells, metastasis, and infiltrating macrophages.

Authors:  Shengnan Zhang; Violeta Chitu; E Richard Stanley; Bruce E Elliott; Peter A Greer
Journal:  Cancer Res       Date:  2010-12-15       Impact factor: 12.701

2.  Small-molecule inhibitors of the c-Fes protein-tyrosine kinase.

Authors:  Sabine Hellwig; Chandra V Miduturu; Shigeru Kanda; Jianming Zhang; Panagis Filippakopoulos; Eidarus Salah; Xianming Deng; Hwan Geun Choi; Wenjun Zhou; Wooyoung Hur; Stefan Knapp; Nathanael S Gray; Thomas E Smithgall
Journal:  Chem Biol       Date:  2012-04-20

3.  Methylator phenotype of malignant germ cell tumours in children identifies strong candidates for chemotherapy resistance.

Authors:  J N Jeyapalan; D A Mohamed Noor; S-H Lee; C L Tan; V A Appleby; J P Kilday; R D Palmer; E C Schwalbe; S C Clifford; D A Walker; M J Murray; N Coleman; J C Nicholson; P J Scotting
Journal:  Br J Cancer       Date:  2011-06-28       Impact factor: 7.640

4.  Bimolecular fluorescence complementation demonstrates that the c-Fes protein-tyrosine kinase forms constitutive oligomers in living cells.

Authors:  Jonathan M Shaffer; Sabine Hellwig; Thomas E Smithgall
Journal:  Biochemistry       Date:  2009-06-09       Impact factor: 3.162

5.  Overexpression of FES might inhibit cell proliferation, migration, and invasion of osteosarcoma cells.

Authors:  Yang Zhao; Zhimeng Wang; Qian Wang; Liang Sun; Ming Li; Cheng Ren; Hanzhong Xue; Zhong Li; Kun Zhang; Dingjun Hao; Na Yang; Zhe Song; Teng Ma; Yao Lu
Journal:  Cancer Cell Int       Date:  2020-03-30       Impact factor: 5.722

6.  Molecular characterization of colorectal adenomas with and without malignancy reveals distinguishing genome, transcriptome and methylome alterations.

Authors:  Brooke R Druliner; Panwen Wang; Taejeong Bae; Saurabh Baheti; Seth Slettedahl; Douglas Mahoney; Nikolaos Vasmatzis; Hang Xu; Minsoo Kim; Matthew Bockol; Daniel O'Brien; Diane Grill; Nathaniel Warner; Miguel Munoz-Gomez; Kimberlee Kossick; Ruth Johnson; Mohamad Mouchli; Donna Felmlee-Devine; Jill Washechek-Aletto; Thomas Smyrk; Ann Oberg; Junwen Wang; Nicholas Chia; Alexej Abyzov; David Ahlquist; Lisa A Boardman
Journal:  Sci Rep       Date:  2018-02-16       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.